Intervention
Echocardiography Test
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 33 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
33 shownTesting the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerNCT07137416 · 2026-10-05
RECRUITINGSotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationNCT07012031 · 2026-06-17
RECRUITINGGT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung CancerNCT07017829 · 2026-04-01
RECRUITINGTarlatamab for the Treatment of Extensive Stage Small-cell Lung CancerNCT07423585 · 2026-03-20
RECRUITINGTesting the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerNCT06287775 · 2025-04-08
RECRUITINGCell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerNCT06236139 · 2024-11-26
RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07
RECRUITINGPersonalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerNCT05098210 · 2022-06-09
RECRUITINGOsimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung CancerNCT04780568 · 2022-01-18
RECRUITINGOsimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28
RECRUITINGTesting the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16
RECRUITINGA Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In SituNCT04144023 · 2019-06-27
RECRUITINGTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · 2019-05-13
RECRUITINGTesting Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeNCT03191149 · 2018-04-25
RECRUITINGAdding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisNCT07578116 · 2027-03-09
NOT_YET_RECRUITINGIL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate CancerNCT07803653 · 2026-10-31
NOT_YET_RECRUITINGAMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")NCT07649304 · 2026-10-09
NOT_YET_RECRUITINGTesting the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerNCT06732401 · 2025-08-07
ACTIVE_NOT_RECRUITINGIbrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell TransplantNCT06271616 · 2024-12-13
TERMINATEDTesting the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)NCT05554354 · 2024-09-13
TERMINATEDTesting the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeNCT04929041 · 2022-10-07
ACTIVE_NOT_RECRUITINGTherapy Adapted for High Risk and Low Risk HIV-Associated Anal CancerNCT04929028 · 2022-08-09
ACTIVE_NOT_RECRUITINGTesting the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialNCT04704661 · 2021-08-09
ACTIVE_NOT_RECRUITINGTesting the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerNCT04310007 · 2020-07-13
ACTIVE_NOT_RECRUITINGTesting the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerNCT03939897 · 2020-06-17
ACTIVE_NOT_RECRUITINGTesting Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)NCT06385483 · 2018-02-28
ACTIVE_NOT_RECRUITINGTesting Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)NCT06136897 · 2017-03-23
ACTIVE_NOT_RECRUITINGNivolumab and Ipilimumab in Treating Patients With Rare TumorsNCT02834013 · 2017-01-30
ACTIVE_NOT_RECRUITINGNivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)NCT02595944 · 2016-07-22
ACTIVE_NOT_RECRUITINGOsimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorNCT02496663 · 2016-05-11
ACTIVE_NOT_RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITINGGenetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)NCT02194738 · 2014-09-26
ACTIVE_NOT_RECRUITINGCediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast CancerNCT01116648 · 2010-04-14
ACTIVE_NOT_RECRUITINGCommon conditions
Stage IV Lung Cancer AJCC v89Anatomic Stage IV Breast Cancer AJCC v87Metastatic Lung Non-Small Cell Carcinoma5Stage IIIB Lung Cancer AJCC v85Advanced Malignant Solid Neoplasm4Metastatic HER2-Negative Breast Carcinoma4Metastatic Hormone Receptor-Positive Breast Carcinoma4Metastatic Malignant Solid Neoplasm4Anatomic Stage III Breast Cancer AJCC v83Lung Non-Small Cell Carcinoma3Metastatic Breast Carcinoma3Recurrent Lung Non-Small Cell Carcinoma3Stage III Lung Cancer AJCC v83Stage IIIA Lung Cancer AJCC v83Stage IVB Prostate Cancer AJCC v83Unresectable Malignant Solid Neoplasm3Advanced Lung Non-Small Cell Carcinoma2Advanced Lymphoma2Bladder Adenocarcinoma2Extensive Stage Lung Small Cell Carcinoma2Malignant Solid Neoplasm2Metastatic HER2-Positive Breast Carcinoma2Metastatic Lung Non-Squamous Non-Small Cell Carcinoma2Recurrent Breast Carcinoma2Recurrent Lung Non-Squamous Non-Small Cell Carcinoma2
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING14
RECRUITING14
NOT_YET_RECRUITING3
TERMINATED2
Phase mix
PHASE218
PHASE113
PHASE36
NA1
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.